ANDA 201823, held by Watson Laboratories. Rasagiline Mesylate.
As of Nov 20, 2026, ANDA 201823 (Rasagiline Mesylate), held by Watson Laboratories, was first approved by FDA on Jul 1, 2013, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2013 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Discontinued |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters